Understanding the characteristics and treatment of patients with ATTR amyloidosis

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to gather real-world evidence on the disease journeys of patients diagnosed with ATTR amyloidosis. It will analyze baseline characteristics, treatment patterns, and various clinical, economic, and humanistic outcomes, such as quality of life and daily living activities. The study will follow patients longitudinally to assess healthcare resource utilization and outcomes both pre- and post-diagnosis. By characterizing these factors, the study seeks to provide a comprehensive understanding of how ATTR amyloidosis presents and is managed.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients aged \>18 years at study index date AND
* A reported diagnosis code for amyloidosis OR
* A claim for ATTR-specific treatment OR
* A positive biopsy for amyloidosis and positive immunostaining result of biopsy for ATTR

Exclusion Criteria:

* Evidence of primary (AL) and secondary (AA) amyloidosis AND/OR
* At least one claim/procedure code for stem cell transplant or at least two claims/procedure codes for chemotherapy and autoimmune disease drugs which may represent AL (primary) or AA (secondary) amyloidosis treatments

Where it's running

• Research Site
  Lecce, Italy Recruiting
• Research Site
  Messina, Italy Recruiting
• Research Site
  Milan, Italy Recruiting
• Research Site
  Lisbon, Portugal Recruiting
• Research Site
  Porto, Portugal Recruiting
• Research Site
  Eden Prairie, Minnesota, United States Completed

Study contacts

• Study coordinator: AstraZeneca Clinical Study Information Center
• Email: information.center@astrazeneca.com
• Phone: 1-877-240-9479

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Hungarian National Systemic Amyloidosis Registry

  This registry collects medical data from adults with systemic amyloidosis across Hungary to help understand how the disease is diagnosed and treated in real-world practice.

  Recruiting at 12 sites Semmelweis University · Balatonfüred and 11 other locations · NCT07689331

• Registry for patients with ATTR amyloidosis

  This study is creating a detailed registry for people with ATTR amyloidosis to track their health over time and help doctors understand the disease better.

  Recruiting Fondazione IRCCS Policlinico San Matteo di Pavia · Legnano, MI and 29 other locations · NCT05444920

• Observational study of patients with ATTR amyloidosis

  This study looks at the characteristics of people with ATTR amyloidosis and tests how well existing treatments work for them in real life.

  Recruiting at 38 sites Alnylam Pharmaceuticals · La Jolla, California and 39 other locations · NCT04561518

• Understanding Atrioventricular Regurgitation in ATTR Amyloid Cardiomyopathy

  This study is trying to understand how common certain heart valve problems are in people with ATTR amyloid cardiomyopathy and create better ways to measure their severity.

  Recruiting at 8 sites Medical University of Vienna · Graz, Styria and 7 other locations · NCT06836011

• Diagnosing ATTR Cardiac Amyloidosis in Patients with Carpal Tunnel Syndrome

  This study is testing if patients with carpal tunnel syndrome might also have a heart condition called ATTR amyloidosis by doing tests and following them for 10 years.

  Recruiting Helse Møre og Romsdal HF · Ålesund, Møre og Romsdal · NCT06458374

• Effects of dobutamine on heart function in patients with a specific type of heart disease

  This study is testing whether dobutamine can help improve heart function in older patients with a specific type of heart disease called wild-type Transthyretin Amyloid Cardiomyopathy.

  Recruiting Phase 1/2 Aarhus University Hospital Skejby · Aarhus · NCT06318260

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.